Literature DB >> 13678829

Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro.

Malthe M Kristiansen1, Clara Leandro, Diane Ordway, Marta Martins, Miguel Viveiros, Teresa Pacheco, Jette E Kristiansen, Leonard Amaral.   

Abstract

Mechanisms of antibiotic resistance of bacteria include efflux pumps which extrude the antibiotic prior to reaching its target. Phenothiazines inhibit the activity of some efflux pumps thereby altering the susceptibility of bacteria. This study demonstrated that chlorpromazine and thioridazine reduce the susceptibility of methicillin-resistant strains (MRSA) but not that of methicillin-susceptible Staphylococcus aureus (MSSA) strains to oxacillin (MIC of oxacillin reduced from >500 to 10 mg/l). Reserpine, an inhibitor of antibiotic efflux pumps also reduced the resistance of MRSA strains to oxacillin suggesting the presence of an efflux pump that contributes to antibiotic resistance of MRSA strains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678829     DOI: 10.1016/s0924-8579(03)00200-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 2.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 3.  Thioridazine: resurrection as an antimicrobial agent?

Authors:  H K R Thanacoody
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

4.  Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity.

Authors:  Michael Stenger; Carsten Behr-Rasmussen; Kasper Klein; Rasmus B Grønnemose; Thomas Emil Andersen; Janne K Klitgaard; Hans Jørn Kolmos; Jes S Lindholt
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

5.  Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis.

Authors:  Meeta J Advani; Imran Siddiqui; Pawan Sharma; Hemalatha Reddy
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

6.  Assessments of Thioridazine as a Helper Compound to Dicloxacillin against Methicillin-Resistant Staphylococcus aureus: In Vivo Trials in a Mouse Peritonitis Model.

Authors:  Michael Stenger; Kristoffer Hendel; Peter Bollen; Peter B Licht; Hans Jørn Kolmos; Janne K Klitgaard
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

7.  Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them.

Authors:  Leonard Amaral; Ana Martins; Gabriella Spengler; Joseph Molnar
Journal:  Front Pharmacol       Date:  2014-01-03       Impact factor: 5.810

8.  Propyl-5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC): a new bacteriostatic agent against methicillin-resistant Staphylococcus aureus.

Authors:  Tatiana Johnston; Daria Van Tyne; Roy F Chen; Nicolas L Fawzi; Bumsup Kwon; Michael J Kelso; Michael S Gilmore; Eleftherios Mylonakis
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

9.  A Novel Derivative of Thioridazine Shows Low Toxicity and Efficient Activity against Gram-Positive Pathogens.

Authors:  Nadia S Jørgensen; Lasse Saaby; Anne M Andersson; Sofie Kromann; Ehsan Sheikhsamani; Anders Permin; Troels Ronco; Søren W Svenningsen; Jørn B Christensen; Rikke H Olsen
Journal:  Antibiotics (Basel)       Date:  2020-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.